April 18th 2024
A study presented at the Society for Healthcare Epidemiology of America (SHEA) conference assesses the link between antibiotic use and C difficile infection in Tennessee.
COVID-19 Public Health Emergency Is Over. What Have We Learned?
June 7th 2023As the official COVID-19 emergency is declared over, our Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reflects on the public health response, the scientific successes, and the shortcomings that were experienced.
Read More
Can I Get a Break From Candida auris?
June 6th 2023With the CDC’s recent warning about it, this fungal infection is becoming more prevalent and is often multidrug resistant. Here are some infection prevention strategies to protect against its spread in health care facilities, where it is most common.
Read More
LMN-201 Fast Tracked by FDA as a Potential Breakthrough Treatment for C diff Infection
May 17th 2023LMN-201, an oral biologic drug developed by Lumen Bioscience, has received Fast Track Designation from the FDA. The drug combines therapeutic proteins to neutralize the bacterium and toxin that cause C difficile infection.
Read More
Patient Perspectives on Rectal Administration for Recurrent C difficile Infection
May 15th 2023A study of patients with recurrent Clostridioides difficile infection (rCDI) found that Rebyota, a rectally administered live biotherapeutic, was considered easy, quick, and appealing due to the lack of bowel preparation.
Read More